Simultaneous quantification of the new HIV protease inhibitors atazanavir and tipranavir in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry
- 25 May 2004
- journal article
- research article
- Published by Elsevier in Journal of Chromatography B
- Vol. 804 (2), 359-367
- https://doi.org/10.1016/j.jchromb.2004.01.041
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Fragmentation pathways of sulphonamides under electrospray tandem mass spectrometric conditionsRapid Communications in Mass Spectrometry, 2003
- Liquid chromatography-tandem mass spectrometric quantitative determination of the HIV protease inhibitor atazanavir (BMS-232632) in human peripheral blood mononuclear cells (PBMC): practical approaches to PBMC preparation and PBMC assay design for high-throughput analysisJournal of Chromatography B, 2003
- Quantitative determination of the HIV protease inhibitor atazanavir (BMS-232632) in human plasma by liquid chromatography–tandem mass spectrometry following automated solid-phase extractionJournal of Chromatography B, 2003
- Rapid quantification of HIV protease inhibitors in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometryJournal of Mass Spectrometry, 2003
- AtazanavirDrugs, 2003
- TipranavirDrugs, 2003